Generic selectors
Exact matches only
Search in title
Search in content
Filter by Categories
Backgrounder
Biosimilars Bulletin
Blog
Council Resource
Event
Handbook
Infographic
Issue Brief
Media
Member Spotlight
Partner Resource
Policy Recommendation
Press Release
Report
Statement
Video
Whitepapers

2021 U.S. Generic and Biosimilar Medicines Savings Report

The report proves that the promise of biosimilars is coming to fruition. As patient access to lower-cost biosimilars grew in 2020, savings skyrocketed.

Learn More

Biosimilars are a prescription for better health.

Biosimilars could lead to over $130 billion in savings by 2025, giving 1.2 million patients access to needed medicines.

Learn More

Access! 2022

Access! brings together policymakers, influential speakers and industry leaders to chart the future of generics and biosimilars. Plan to join us in person for the first time since 2019 in Orlando, FL!  Sign up before December 31, 2021 to receive $500 off full-pass registration.
Events
About Us
Resources
Media

The Basics of Biosimilars

Biosimilars Council, Biosimilars Council

secure our meds white paper

Roadmaps for Ensuring Patient Access to Generic and Biosimilar Medicines

This paper examines the challenges to market sustainability for generic and biosimilar medicines that have cleared the regulatory and patent hurdles to obtain FDA approval and launch into the U.S. market.

LEARN MORE

Browse our Resources

Hear more from experts on the potential of biosimilars and learn about Biosimilars Council efforts to increase biosimilar access for patients.

ALL RESOURCES

Biosimilars Council, Biosimilars Council
Event
November 29, 2021
GRx+Biosims 2021 Conference Recap
Biosimilars Council, Biosimilars Council
Blog
October 28, 2021
Patients Increasingly Rely on Oncology Biosimilar Medicines
Biosimilars Council, Biosimilars Council
Blog
October 14, 2021
AAM Annual Savings Report – Biosimilars and Bending the Cost Curve
patient access to biosimilars
Blog
July 27, 2021
Increase Patient Access to Lower-Cost Biosimilar Medicines
The Biosimilars Council - Doctors with hands in the middle
Blog
July 1, 2021
Organizations Thank Rep. Schrader, Kinzinger for Introducing the BIOSIM Act
Biosimilars Council, Biosimilars Council
Blog
June 28, 2021
Increasing Provider Reimbursement for Biosimilars Will Lead to Greater Adoption

Want to keep up-to-date?

Enter your email address below and receive the Biosimilars Bulletin – our monthly newsletter with the most recent information on biosimilars in the United States.

  • This field is for validation purposes and should be left unchanged.

FDA Biosimilars Approvals

Find an up-to-date list of FDA approved biosimilars and launches.

LEARN MORE

Featured Reports & Resources

These resources provide answers around what biosimilars are, why they are important, how they can improve patient access, and how they can save the United States billions of dollars.

Biosimilars Council, Biosimilars Council
Biosimilars Council, Biosimilars Council
Biosimilars Council, Biosimilars Council
failure to launch white paper

Recent Tweets

Biosimilars CouncilFollow2,15610,190

Biosimilars Council works to ensure a positive environment for patient access to biosimilar medicines. Division of @AccessibleMeds | https://t.co/0jAeG0TOPj

Biosimilars Council
BiosimsCouncil avatarBiosimilars Council@BiosimsCouncil·
9h 1466166578232320001

Build Back Better aims to reduce drug prices, but its short-term solution would only damage the #biosimilars industry in the long run and reduce access for America's patients.

Learn more to see how this bill could undermine patients' access to care: https://bit.ly/2ZyFYFA

Twitter feed video.
Image for the Tweet beginning: Build Back Better aims to
Reply on Twitter 1466166578232320001Retweet on Twitter 1466166578232320001Like on Twitter 1466166578232320001Twitter 1466166578232320001
Load More...